Phenethylamine

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: mood energy focus

Research Overview

Across the provided abstracts, phenethylamine (PEA) research is most developed in two intersecting areas: (1) phenethylamine-related psychoactive drugs (notably amphetamines and synthetic cathinones) and their neuropharmacology/toxicology, and (2) emerging roles of endogenously produced PEA from the gut microbiome in metabolic disease. The synthetic cathinone literature is particularly extensive and surveillance-driven (e.g., EU Early Warning System monitoring of a large and expanding set of compounds), with multiple systematic reviews emphasizing clinical intoxications, fatalities, and mechanistic toxicology. In parallel, mechanistic work on stimulant neurotoxicity (exemplified by methamphetamine as a phenethylamine/amphetamine-class compound) has focused on monoaminergic dysregulation and downstream cellular stress pathways. A smaller but mechanistically specific line of research links microbial PEA production (e.g., by Ruminococcus gnavus) to host insulin resistance via trace amine-associated receptor 1 (TAAR1) and ERK signaling.

The strongest evidence in these abstracts supports two conclusions. First, phenethylamine-structured stimulants—especially synthetic cathinones—are associated with a broad spectrum of acute neuropsychiatric and neurologic harms in humans (e.g., agitation/psychosis, encephalopathy, coma, convulsions) and can produce severe toxidromes (sympathomimetic, hallucinogenic), including risks consistent with excited delirium and serotonin syndrome; animal models (rats, mice, zebrafish larvae) corroborate brain-related adverse effects and provide mechanistic plausibility. Second, there is convergent associative and experimental evidence that microbiota-derived PEA can causally impair insulin signaling: human observational associations (higher R. gnavus/PEA levels with insulin resistance in IBS and T2D) are complemented by gnotobiotic mouse monoassociation experiments and metabolite administration studies in mice and monkeys, implicating a TAAR1–ERK axis as a mediating pathway.

Key gaps remain. For synthetic cathinones and related phenethylamine derivatives, reviews highlight that neurotoxicity is less characterized than cardiovascular toxicity, and the rapid emergence of new analogs outpaces controlled pharmacokinetic/pharmacodynamic profiling, standardized toxicology, and longitudinal outcome studies; improved attribution is also needed in real-world settings where polysubstance exposure is common and reporting may be incomplete (e.g., during the COVID-19 period). For microbiome-derived PEA, further research is needed to establish dose–response relationships, inter-individual variability (diet, microbiome composition, host genetics), and the translational relevance of TAAR1-targeted interventions in well-controlled human trials, including whether PEA is a biomarker, a mediator, or both across IBS-metabolic syndrome comorbidity. More generally, integrating mechanistic receptor/transport studies (e.g., DAT and TAAR1 signaling) with clinical phenotyping and rigorous epidemiology would strengthen causal inference and therapeutic development.

1. What conditions has Phenethylamine been studied for?

  • Metabolic dysfunction / insulin resistance (including type 2 diabetes) and metabolic syndrome risk in IBS: One abstract reports that Ruminococcus gnavus-derived phenethylamine (along with tryptamine) is associated with insulin resistance in patients with type 2 diabetes (T2D) and irritable bowel syndrome (IBS), and mechanistically impairs insulin signaling via TAAR1–ERK signaling.

  • Substance use and stimulant pharmacology (drug development context): A review of dopamine transporter (DAT) ligands discusses phenethylamine- or cathinone-derived DAT substrates/inhibitors as potential approaches for treating stimulant-use disorders (i.e., as substitution/antagonist strategies), though this is about drug-design scaffolds rather than phenethylamine as a supplement.

  • Neurotoxicity and acute intoxication from phenethylamine-related stimulants: Multiple abstracts focus on synthetic cathinones (phenethylamine-related stimulants) and methamphetamine (a phenethylamine/amphetamine-class drug), describing severe neuropsychiatric and systemic toxicity, intoxications, and fatalities.

  • Psychedelic use/mental health outcomes (phenethylamine derivatives): Mescaline (a phenethylamine derivative) is discussed in survey and review abstracts, including epidemiology of use and mechanisms (primarily serotonergic 5-HT2A/2C activity) with reported subjective/mental health-related outcomes.

  • Dietary supplement safety/regulatory issues: A regulatory review describes biologically active phenethylamines (including synthetic analogs such as β-methylphenethylamines) appearing in dietary supplements and weight-loss products, emphasizing misbranding/adulteration and FDA actions.

2. Does it work in treating those conditions? Summarize the evidence.

  • Insulin resistance / metabolic syndrome in IBS and T2D: The evidence in the abstracts does not support phenethylamine as a treatment; rather, it suggests a pathogenic role. The abstract reports that phenethylamine levels (derived from R. gnavus) are positively associated with insulin resistance in T2D and IBS patients, and that administering phenethylamine impaired insulin signaling in healthy mice and monkeys via a TAAR1–ERK axis.

  • Stimulant-use disorder treatment (DAT-targeting concepts): The DAT-ligand review suggests that certain phenethylamine/cathinone-derived compounds can have “atypical” DAT-inhibitor effects and may be explored as treatments for stimulant abuse. However, this is mechanistic and preclinical/medicinal-chemistry rationale in the abstract, not clinical proof that phenethylamine itself treats stimulant-use disorder.

  • Mental health/therapeutic outcomes (mescaline derivative): A web-based survey abstract reports that mescaline users commonly used it infrequently and reported few legal/psychological problems and no medical attention, with perceived spiritual significance and mental health improvements. This is self-reported, observational survey evidence and pertains to mescaline (a substituted phenethylamine), not phenethylamine as a dietary supplement or medication.

  • Neurotoxicity/intoxication literature: The synthetic cathinone systematic review and methamphetamine review describe harms and mechanisms of damage (e.g., persistent monoaminergic terminal damage for methamphetamine; encephalopathy/coma/convulsions and toxidromes for synthetic cathinones). These do not support therapeutic efficacy; they support risk.

Bottom line from these abstracts: There is no direct evidence here that phenethylamine is an effective treatment for a medical condition. The clearest causal evidence presented links phenethylamine (microbiome-derived) to worsened insulin signaling, not improvement.

3. What health benefits does it have?

  • No clear, direct health benefit for phenethylamine itself is demonstrated in the provided abstracts. The abstracts primarily discuss phenethylamine in the context of:

    • Potential harm in metabolism (microbiome-derived phenethylamine impairing insulin signaling via TAAR1–ERK).

    • Drug scaffolds/medicinal chemistry (2-phenethylamines as motifs in medicinal chemistry; DAT-ligand development concepts), which indicates research interest but not proven consumer health benefits.

    • Phenethylamine derivatives (e.g., mescaline) that may have subjective or mental health-related outcomes in survey data, but that evidence does not establish benefits of phenethylamine itself.

4. Does it have any downsides or side effects?

  • Metabolic downside (microbiome-derived phenethylamine): The IBS/T2D abstract reports phenethylamine is positively associated with insulin resistance in patients, and that phenethylamine administration impaired insulin signaling in major metabolic tissues of mice and monkeys via TAAR1–ERK signaling—consistent with a potential role in worsening glucose control.

  • Neuropsychiatric and systemic toxicity in phenethylamine-related stimulants (class effects): While not phenethylamine itself, the abstracts emphasize that phenethylamine-related stimulant drugs (synthetic cathinones; methamphetamine) can cause severe adverse outcomes. Reported effects include:

    • Severe neurotoxicity and neurologic events (synthetic cathinones): encephalopathy, coma, convulsions; sympathomimetic and hallucinogenic toxidromes; risk of excited/agitated delirium syndrome and serotonin syndrome; and fatalities (systematic review of 76 included studies).

    • Persistent monoaminergic terminal damage (methamphetamine review): persistent damage to dopamine and serotonin release in nerve terminals, gliosis, and apoptosis, with multiple implicated mechanisms (e.g., excessive dopamine, ER stress, inflammatory pathways).

    • Public health harms and fatalities from NPS during COVID-19: a review identified numerous NPS exposures and fatalities during the pandemic period, with synthetic cathinones among the more common classes reported.

  • Supplement quality/adulteration risks: The FDA-focused review highlights that biologically active phenethylamines (including synthetic analogs) have been found in dietary supplements and weight-loss products, with concerns about misbranding/adulteration and regulatory actions. This implies a practical safety risk: consumers may ingest stimulant-like phenethylamines unintentionally or at undisclosed doses.

  • For phenethylamine specifically: The provided abstracts do not enumerate a clinical side-effect profile for phenethylamine as a standalone supplement (dose, frequency, acute adverse event rates). The strongest direct signal in these abstracts is the mechanistic/metabolic impairment finding (TAAR1–ERK; insulin signaling).

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report pharmacogenomic findings (i.e., specific genetic variants that alter phenethylamine response, safety, or efficacy). They do, however, identify a receptor pathway that could plausibly vary between individuals:

  • TAAR1 pathway (mechanistic target, not a genetic result): The IBS/T2D abstract attributes phenethylamine’s insulin-signaling impairment to the TAAR1–ERK signaling axis. While this suggests that inter-individual differences in TAAR1 signaling could matter, the abstracts do not provide evidence linking specific TAAR1 (or other) genetic variants to differential outcomes.

Conclusion: Based on these abstracts alone, no genotype-specific recommendations (beneficial or harmful) can be made for phenethylamine.

References

  1. Synthetic Cathinones and Neurotoxicity Risks: A Systematic Review.
    Gloria Daziani, Alfredo Fabrizio Lo Faro, Vincenzo Montana, Gaia Goteri, Mauro Pesaresi, Giulia Bambagiotti, Eva Montanari, Raffaele Giorgetti, Angelo Montana (2023) - International journal of molecular sciences
  2. An updated review on synthetic cathinones.
    Jorge Soares, Vera Marisa Costa, Maria de Lourdes Bastos, Félix Carvalho, João Paulo Capela (2021) - Archives of toxicology
  3. Gut microbiota-derived tryptamine and phenethylamine impair insulin sensitivity in metabolic syndrome and irritable bowel syndrome.
    Lixiang Zhai, Haitao Xiao, Chengyuan Lin, Hoi Leong Xavier Wong, Yan Y Lam, Mengxue Gong, Guojun Wu, Ziwan Ning, Chunhua Huang, Yijing Zhang, Chao Yang, Jingyuan Luo, Lu Zhang, Ling Zhao, Chenhong Zhang, Johnson Yiu-Nam Lau, Aiping Lu, Lok-Ting Lau, Wei Jia, Liping Zhao, Zhao-Xiang Bian (2023) - Nature communications
  4. Recent advances in methamphetamine neurotoxicity mechanisms and its molecular pathophysiology.
    Shaobin Yu, Ling Zhu, Qiang Shen, Xue Bai, Xuhui Di (2015) - Behavioural neurology
  5. The polypharmacology of psychedelics reveals multiple targets for potential therapeutics.
    Manish K Jain, Ryan H Gumpper, Samuel T Slocum, Gavin P Schmitz, Jakob S Madsen, Tia A Tummino, Carl-Mikael Suomivuori, Xi-Ping Huang, Laura Shub, Jeffrey F DiBerto, Kuglae Kim, Chelsea DeLeon, Brain E Krumm, Jonathan F Fay, Michael Keiser, Alexander S Hauser, Ron O Dror, Brian Shoichet, David E Gloriam, David E Nichols, Bryan L Roth (2025) - Neuron
  6. New Psychoactive Substances Intoxications and Fatalities during the COVID-19 Epidemic.
    Alfredo Fabrizio Lo Faro, Diletta Berardinelli, Tommaso Cassano, Gregory Dendramis, Eva Montanari, Angelo Montana, Paolo Berretta, Simona Zaami, Francesco Paolo Busardò, Marilyn Ann Huestis (2023) - Biology
  7. Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter.
    Maarten E A Reith, Bruce E Blough, Weimin C Hong, Kymry T Jones, Kyle C Schmitt, Michael H Baumann, John S Partilla, Richard B Rothman, Jonathan L Katz (2015) - Drug and alcohol dependence
  8. The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects.
    Malin Vedøy Uthaug, Alan K Davis, Trevor Forrest Haas, Dawn Davis, Sean B Dolan, Rafael Lancelotta, Christopher Timmermann, Johannes G Ramaekers (2022) - Journal of psychopharmacology (Oxford, England)
  9. Overview of regulation of dietary supplements in the USA and issues of adulteration with phenethylamines (PEAs).
    Rahul S Pawar, Erich Grundel (2017) - Drug testing and analysis
  10. Pharmacology and Toxicology of N-Benzylphenethylamine ("NBOMe") Hallucinogens.
    Adam L Halberstadt (2017) - Current topics in behavioral neurosciences
  11. 2-Phenethylamines in Medicinal Chemistry: A Review.
    Carlos T Nieto, Alejandro Manchado, Leland Belda, David Diez, Narciso M Garrido (2023) - Molecules (Basel, Switzerland)
  12. Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions.
    Ricardo Jorge Dinis-Oliveira, Carolina Lança Pereira, Diana Dias da Silva (2019) - Current molecular pharmacology
  13. A health risk for consumers: the presence of adulterated food supplements in the Netherlands.
    Jacqueline W H Biesterbos, Dick T H M Sijm, Ruud van Dam, Hans G J Mol (2019) - Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment
  14. Associations between classic psychedelics and nicotine dependence in a nationally representative sample.
    Grant Jones, Joshua Lipson, Matthew K Nock (2022) - Scientific reports
  15. The Black Book of Psychotropic Dosing and Monitoring.
    Charles DeBattista, Alan F Schatzberg (2024) - Psychopharmacology bulletin
  16. Neurochemical and Behavioral Profiling in Male and Female Rats of the Psychedelic Agent 25I-NBOMe.
    Cristina Miliano, Matteo Marti, Nicholas Pintori, Maria Paola Castelli, Micaela Tirri, Raffaella Arfè, Maria Antonietta De Luca (2019) - Frontiers in pharmacology
  17. Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged 16 to 17 Years: Rationale Balanced With Caution.
    Jessica K Jeffrey, Marc J Weintraub, Charles S Grob (2024) - Journal of the American Academy of Child and Adolescent Psychiatry
  18. Tolerance to neurochemical and behavioral effects of the hallucinogen 25I-NBOMe.
    Monika Herian, Mateusz Skawski, Adam Wojtas, Małgorzata K Sobocińska, Karolina Noworyta, Krystyna Gołembiowska (2021) - Psychopharmacology
  19. Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics.
    James D Sexton, Charles D Nichols, Peter S Hendricks (2019) - Frontiers in psychiatry
  20. Effect of
    Micaela Tirri, Sabrine Bilel, Raffaella Arfè, Giorgia Corli, Beatrice Marchetti, Tatiana Bernardi, Federica Boccuto, Giovanni Serpelloni, Francesco Botrè, Fabio De-Giorgio, Krystyna Golembiowska, Matteo Marti (2022) - Frontiers in psychiatry


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!